Talazoparib Before Standard Therapy in Treating Patients With Invasive, BRCA-Mutated Breast Cancer

NCT02282345 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

36

Enrollment

OTHER

Sponsor class

Conditions

Breast Adenocarcinoma
Deleterious BRCA1 Gene Mutation
Deleterious BRCA2 Gene Mutation
HER2/Neu Negative
Invasive Breast Carcinoma

Interventions

OTHER: Laboratory Biomarker Analysis
DRUG: Talazoparib

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]